Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Vimian Group, Audiocast, Q4'25

By Inderes2/12/2026, 8:00 AM
Vimian Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Molly
00:00 - 11:09

Good morning, everyone, and welcome to our 2025 year-end and fourth quarter earnings call. I'm Molly, the new Group CEO since the end of last year after leading the Veterinary Services segment for the past four years. To give you some background, during my four years as Head of Veterinary Services, the business developed from a Northern European purchasing organization into a global service platform with over 10,000 member clinics. I've personally experienced the company's ability to attract talent and entrepreneurs and take something relatively, relatively small with potential and build it into global scale and a market leader. I'm a firm believer in our strategy of organic and acquisition-driven growth, and we operate in an exciting and resilient industry going through change. I know the sector, the customers, the business and our organization well, and I'm confident about our industry and future. We will now go through the full year and fourth quarter and will later give you deeper insights into the financials. Looking back at full year 2025, we delivered revenue growth of 13% and adjusted EBITDA growth of 11%. We saw broad-based growth across most of our businesses, not least in Specialty Pharma, Veterinary Services, and our MedTech dental businesses. We also put in focused efforts to address the headwinds within MedTech Orthopedics, in particular in the US. In fall, we received a positive judgment in the US indemnification process, and all counterparts have now, as of year-end, paid us in full. The year also delivered a strong operational cash flow of €105.7 million, corresponding to a cash conversion of 101%. Last but not least, we also completed the list change to Nasdaq Main Market, where we are now a large cap company. Going deeper into Q4 and looking at the quarter, we delivered a solid finish to 2025 with 6% organic growth and 6% adjusted EBITDA growth, excluding currency effects. Adjusted EBITDA grew by 12% excluding currency effects. We saw continued momentum within our Specialty Pharma segment. We saw a strong finish with MedTech Dental while active measures were taken in the quarter. Within MedTech Orthopedics, efforts were ongoing, while Veterinary Services continued to perform at scale, reaching over 10,000 members. And in the quarter, we increased our M&A activity with three acquisitions across three different segments and expanded our M&A pipeline. The past few months ahead of 2026 included I-Vet. An important milestone for the Diagnostics segment was an acquisition signed just before Christmas to strengthen the companion animal offering within that segment. The quarter also delivered strong cash conversion. Looking at Q4, we had 4% revenue growth to €109 million. Our organic revenue growth was 6%, driven by Specialty Pharma, Veterinary Services, and our MedTech dental business, with 3% contributions from acquisitions, and we saw a 4% negative impact from currency movements, in particular, movements in the US dollar. We improved our margin by 60 basis points versus Q4 2024, driven by bolt on acquisitions and delivered 6% adjusted EBITDA growth for the quarter. And as I said before, excluding currency effects, Adjusted EBITDA grew. The growth was 12%. Looking at Specialty Pharma, we continue to see positive performance in the fourth quarter with 6% organic growth following an exceptionally strong Q4 2024, where we reported 22% organic growth, normalizing the positive effects from the national sales campaign in the US in the fourth quarter of 2020. The underlying organic growth was double-digit in the fourth quarter this year. All four therapeutic areas delivered growth in the quarter, with the strongest contribution from our dermatology portfolio. Overall, organic growth continues to be driven by our innovation, cross-selling activities, and veterinary education. Adjusted EBITDA grew 4%, or 7% when adjusted for currency effects, to €13.8 million, which is an all-time high quarter for us. The margin improved from 29.4% to 30%, driven by revenue growth and stronger gross margin for the full year. Specialty Pharma grew 6% to €182.4 million and adjusted EBITA by 10% to €53.9 million. In January, our head of Specialty Pharma, Magnus, announced his departure after ten years in the company. I believe the business stands strong, and the recruitment process for a successor is ongoing, and we've secured a strong transition plan with Karl-Johan as interim head of Specialty Pharma. As interim head of MedTech since the end of July. I'm happy to see the accelerated momentum in our dental business in the quarter, as well as early operational improvements within our orthopedic business, although we still have work to be done and the market remains soft. In total, we delivered 4% organic growth in the fourth quarter, supported by strong growth in our dental business and orthopedics in Europe and APAC. Within orthopedics, we have implemented a reorganization in the quarter with a focus on strengthening commercial performance. We built out our field sales organization in the US, and we reviewed and rationalized our product portfolio, where we had over 22,000 SKUs and have decided to discontinue over 4,000 overlapping SKUs. We are still in a transition phase in US Orthopedics during early 2026. We continue to drive sequential sales improvements, but do not expect Orthopedics to deliver year-on-year growth until later in spring. The recruitment for a permanent head of MedTech is ongoing and progressing well. The margin in the quarter of 24.6% is a 370 basis point improvement versus Q4 2024, mainly driven by the consolidation of the Bolton acquisition within dentistry in 2025. Adjusted EBITDA grew 23% in the quarter and 32% excluding currency effects. For the full year, MedTech grew revenues by 25% to €155.5 million. Where our acquisitions within dentistry contributed 30%, full year adjusted EBITDA grew 15% to€39.6 million. Veterinary services delivered another strong quarter with 10% organic growth. In October, we completed the acquisition of a local service platform in Belgium with 300 member clinics and passed the 10,000 milestone when it comes to member clinics, closing the year with 10,900 member clinics. As previously communicated, we are accelerating our investments into new geographies and services in the quarter, taking the margin to 26.6% for the full year. Veterinary Services increased revenues by 11% to €64.3 million, and adjusted EBITDA grew 9% to €18.4 million. Michael Tunnell, who has been part of Veterinary Services since 2018, was appointed Head of Veterinary Services when I became CEO, and I'm pleased to see how the team has come together and continues to build momentum for the global Veterinary Services platform. Our diagnostic business reported 5% organic growth in the quarter and a margin of 9.2%, reflecting our investments in new products and personnel to strengthen the companion animal offering. The growth was supported by bluetongue outbreaks in Europe and avian influenza globally. For the full year, Diagnostics grew by 9% to €22.9 million, while adjusted EBITDA declined 3% to €2.2 million. As I said initially, we welcomed five new businesses in 2025 that expanded our portfolio and geographic footprint. We've seen improving M&A momentum towards the end of the year, with three out of these five acquisitions coming in the fourth quarter. We've built a stronger pipeline over the past months, and I'm optimistic about the M&A opportunities going into 2026. We continue to focus on successful, entrepreneurial-led businesses that can grow and reach their full potential faster as part of Immune. A good example of that is I-Vet that we signed in December. I-Vet is one of the top three in companion animal diagnostics in Italy and forms an important addition to our diagnostic segment. I-Vet is a typical acquisition, a high-growth, successful, and entrepreneurial-led business where the entrepreneur, Daniela, is highly motivated and will continue to lead the business as part of Immune. Annual revenues of €5.6 million, with two thirds of their revenues coming from laboratory services (they have three labs in Italy), and the remaining third from sales of in-clinic diagnostic tests. I-Vet also has a well-known educational platform with over 100 courses annually, and offers residency programs in partnership with universities. Looking at our sustainability as we now close 2025, we can see that we continue to make important progress within our ESG agenda. Our sustainability agenda is closely integrated into the core of the business and focuses on animal health, our people, and the planet. During 2025, we educated 65,000 veterinary professionals to improve animal health, and we launched 94 new products to advance veterinary medicine. Our Employee Net Promoter score reached 30, and we have exceptionally high scores from our teams in areas of inclusion, trust and autonomy. On the environmental side, we continue to reduce our emissions by a total of 25% since 2022. We also received external recognition for our work, with an improved rating at both MSCI to AA and Sustainalytics to low risk. With that run through of the year and the quarter, I will now hand over to you.

Unknown 1
11:12 - 16:38

Thank you Ollie. And let me give you some further insights to the financials for the fourth quarter and full year. Adjusted EBITDA in the fourth quarter was €26.1 million, an increase of 6%. This represents a margin of 24.0% for the quarter. The margin increase is primarily an effect of consolidation of bolt-on acquisitions within MedTech dentistry during 2025. MedTech is also our largest segment. Specialty Pharma contributed to the margin expansion supported by operational leverage in the business. We report an operating profit of €19.2 million, a significant 54% increase from last year's result of €12.5 million. Items affecting comparability decreased in the quarter and totaled -€0.7 million. The majority of items affecting comparability are related to MedTech. This consists of -€1.6 million in restructuring costs from organizational changes and inventory write-down as a consequence of the product portfolio rationalization, as well as 2.7 million relating to the settlement of an indemnification dispute, net of litigation costs in the US. Indemnification dispute. Acquisition related costs amounted to €1.1 million in total for the group. Net financial items amounted to -€7.5 million and consisted of several main parts: financing expenses of -€4.1 million, with an average interest rate of 4.5% during the quarter; a quarterly discounting impact of -€1.6 million; and a negative impact of -€3.1 million from probability adjustments related to contingent considerations. The probability adjustments primarily relate to stronger performance within our acquired dental businesses. A negative result of €0.7 million from liquidation and divestments of subsidiaries. And lastly, a positive impact of 2.2 million from exchange rate effects on the revaluation of debt. Income tax expense for the quarter was €0.8 million, with an effective tax rate of 7% in the fourth quarter. The tax expense as a percentage of pre-tax profit was positively affected by the recognition of deferred tax on tax losses carried forward at year-end, amounting to 3.7 million. The effective tax rate was inflated by non-deductible expenses, mainly probability adjustments of contingent liabilities. In total, this results in a profit for the period of €12.2 million, with an earnings per share of 2 cents for the quarter. Cash flow from operating activities reached 55.7 million, including a payment from a US indemnification dispute of 28.7 million in the quarter. Cash conversion was 92% for the fourth quarter. Net working capital amounted to €96.6 million at the end of the quarter, equal to 23% of revenue, a decrease from €102.2 million at the end of the third quarter, which equaled 24% of revenue. The majority of the 5.6 million decrease in working capital relates to lower current receivables and an increase in trade payables. Cash flow from investing activities amounted to -€17.5 million, primarily relating to acquisitions, earn out payments and investments in tangible and intangible assets. Cash flow from financing activities amounted to -€35.5 million from repayment of borrowings. At the end of the quarter. Net debt amounted to 245.4 million, which is down from 253.5 million at the end of the third quarter. Cash and cash equivalents amounted to 55.0 million, an increase compared to 51.3 million at the end of September. External lending was 223.3 million at the end of the fourth quarter. This resulted in a leverage at the end of the quarter equal to 2.0x, which is down from 2.1 at the end of the third quarter, and we remain well capitalized with an ability to execute on our strengthened acquisition pipeline. With this financial review, I hand the word back to Olli for concluding remarks.

Molly
16:41 - 17:35

Cash flow from operating activities reached 55.7 million, including payment from US indemnification dispute of 28.7 million in the quarter. We deliver a solid finish to 2025, and we are well positioned in a resilient market that continues to grow. I'm a firm believer in our strategy of combining organic and acquisition-driven growth, and my focus is to accelerate what is working well and address the areas we need to improve. We have an attractive platform for entrepreneurs, and I'm optimistic about our M&A pipeline going into 2026. I hear frequently from industry peers and partners that the entrepreneurial spirit and the quality of our people consistently stands out. This is something we take pride in and will continue to build upon with our focus on global market niches with unmet medical needs and high growth potential. We have a strong team in place, along with the products and services we offer. I'm confident we can deliver a good 2026. Cash flow from investing activities amounted to -€17.5 million, primarily relating to acquisitions, earn-out payments and investments in tangible and intangible assets.

Operator
17:46 - 18:05

If you wish to ask a question, please dial Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Kavya Deshpande from UBS. Please go ahead.

Kavya Deshpande
18:07 - 18:45

Good morning. Thank you for taking my questions. I have a couple, please. The first question was on organic growth from here, following the very good exit in Q4. I understand you don't give annual guidance, but could you give us a sense of how significant an organic acceleration we can expect in 2026? I ask because you have a long-term guidance for double-digit organic growth to 2030. You're at 7% for the first two years of the plan. Consensus has you at high single digits for 26, so that obviously implies quite a ramp towards the end of the decade. Are you comfortable with this cadence? Or do you think we can start to get closer to that double digit organic growth target sooner?

Molly
18:48 - 19:04

Thank you for the question. I think we see the overall animal health market continues to grow and we have positive business momentum, as I said, in most parts of the business. So I think we should be able to deliver good growth in 2026.

Kavya Deshpande
19:06 - 19:32

Brilliant. Cross-selling has been and continues to be a robust contributor to organic growth. And my second question was just on Specialty Pharma and cross-selling initiatives there. If I have it right, its contribution to the divisional organic growth slowed a fair bit sequentially in Q4, Q3, and Q2. Are you just reaching the end of this program? And if not, then how much of a contribution can we expect to come from cross-selling for Specialty Pharma and group organic growth in 2026, please?

Unknown 1
19:33 - 20:06

Yes. So the first was on organic growth from here after the very good exit you've had in Q4. Cross-selling has been and continues to be a robust contributor to organic growth. We saw in 2025, just as we saw in 2024, that one third of the organic growth was driven and supported by our cross-selling initiatives. And we are launching new cross-selling initiatives going forward. In 2026, eight new cross-selling initiatives will be launched. This is why we see a continuous runway for a solid contribution from cross-selling in 2026 and beyond.

Kavya Deshpande
20:09 - 20:18

Just to clarify, is it one third of organic growth in the quarter because the press release says in 2025, and I think the previous ones give it as year to date. But just to confirm, that would be great.

Unknown 1
20:19 - 20:26

The one third is the year to date numbers. So for 2025, a third of the organic growth was supported by cross sales.

Kavya Deshpande
20:27 - 20:29

My first question was on organic growth from here after the very good exit you've had in Q4. I ask because you have long-term guidance for double-digit organic growth to 2030. Fine. Thank you.

Operator
20:35 - 20:39

The next question comes from Adela from Jefferies. Please go ahead.

Adela
20:42 - 21:08

Good morning gentlemen. Congratulations on the new appointment. A couple of questions for me as well. Firstly, if we start with MedTech, I believe you said here that you don't expect an acceleration or a year over year growth until spring. Should we read that as some sort of guidance that you do expect to return to double-digit organic growth by Q2?

Molly
21:11 - 21:47

We see early operational improvements, but we are undergoing significant change with the new sales team fully in place as of January. So I think Q1 or spring will be a transition phase for us, but we continue to drive sequential sales improvements. But we don't expect that, as you said, to deliver year on year growth until later this spring. I think that's all we can say at this stage, but I think I could add that a full recovery will probably require the market to regain momentum as well.

Adela
21:49 - 21:51

And by a full recovery, you mean double digits?

Molly
21:53 - 22:06

Yes. The market remains soft right now. So I think the combination of our efforts into the operational side of the business and the market returning to better growth is needed to get to double digits.

Adela
22:07 - 22:21

I see. And then you mentioned also a number of SKUs being discontinued. Have those already been discontinued, or is this an effort that will take place now in 2026 as part of the new commercial efforts?

Molly
22:23 - 22:33

We've already initiated the work of discontinuing those SKUs, but there are a few that will be transitioned to discontinued now earlier this year as well.

Adela
22:35 - 22:39

Would it be possible to quantify what the impact of that was on sales in 2025?

Molly
22:41 - 22:51

Limited. This is overlapping SKUs. So the SKUs we are discontinuing, we have equivalent products that are better and more relevant for our customers to buy.

Adela
22:52 - 23:07

Okay, great. And then lastly on veterinary services, still a high pace of investments. What is the phasing of that? Do you expect the continuation even in 2026 or a slowdown at some stage?

Molly
23:09 - 23:28

We see continued momentum in Veterinary Services. It's been one of our segments performing very well for a long period of time. And we see that to continue. The investments we are making are to ensure that we capture the full potential and the inbound need we get from our partners and veterinarians across the world.

Adela
23:29 - 23:31

What do you hear from your customers? We see an increased M&A momentum. I'll stop there.

Operator
23:36 - 23:41

The next question comes from Sten Gustafson from ABG Sundal Collier. And we see that to continue.

Sten Gustafson
23:43 - 24:19

With the acquisition of I-Vet in Diagnostics, I think we now have four active verticals looking at interesting bolt-on or platform acquisitions. And good morning. I was wondering if you could give us a little bit of color on the M&A market. Right now, in terms of number of opportunities, price levels on targets, and also where you focus your efforts on and where you want to grow? What specifically are you looking to go after.

Molly
24:21 - 24:53

We see an increased M&A momentum. As we stated, three out of the five acquisitions we made in 2025 happened in Q4. We're also confident about the building of our pipeline going into 2026, where we see ourselves being a good and interesting platform for entrepreneurs within Animal Health to join us. With the acquisition of I-Vet and Diagnostics, I think we now have four active verticals looking at interesting bolt-on or platform acquisitions.

Sten Gustafson
24:57 - 25:06

And in terms of price points, has there been any change? Would you say, compared to a year ago?

Unknown 1
25:09 - 25:35

No, I wouldn't say that. We do not see a change. We have a historical average of approximately nine times EBITDA, and we are around that average. As previously communicated, typically, platform acquisitions such as IM3 within the dental space come with a slightly higher multiple, whereas add-on acquisitions to that come with a lower multiple, but the average is nine times.

Sten Gustafson
25:37 - 25:56

We see an increased M&A momentum. Perfect. The investments we're making are to ensure that we capture the full potential and the inbound need we get from our partners and veterinarians across the world. And then a quick question on the US MedTech market. What do you hear from your customers? What kind of feedback and what do they tell you in terms of the market sentiment and activity levels?

Molly
25:58 - 26:18

I think the feedback from our customers regarding market sentiment going into 2026 is similar to that observed in 2025. But with our approach of now building a field sales team in the US, this allows us to come even closer to our customers and together with them, support them in growing the business into the future.

Sten Gustafson
26:20 - 26:41

But what are they waiting for for the market to return? Is it higher consumer confidence, or what's the inflection point that will drive the market back to normal levels?

Molly
26:45 - 27:00

A simplified question of that is, of course, macroeconomics in general. There is still advanced care. But I think with macroeconomic recovery, we will see impacts on the business as well.

Sten Gustafson
27:01 - 27:03

I think the feedback from our customers is similar going into 2026 to that in 2025 from a market sentiment perspective. I think the feedback from our customers is similar going into 2026 to that in 2025 from a market sentiment perspective.

Operator
27:08 - 27:13

The next question comes from Arvid Nikator from DNB Carnegie. Please go ahead.

Arvid Nikator
27:15 - 27:52

Good morning and thanks for taking my questions. So first off, on Specialty Pharma, do you expect this segment to be able to return to double-digit organic growth in 2026? And if so, it would be great to get your view on what would be the main drivers for this surge in growth. And then secondly, on MedTech, comparisons have become a bit easier, of course, but if we look at the industry data, it seems to have stabilized somewhat since mid-year. Do you view this as a genuine inflection point, and how would you characterize the overall market sentiment right now?

Unknown 1
27:55 - 29:06

Good morning Amy. I'll start with your question on Specialty Pharma. So we have good momentum in Specialty Pharma if we look through the full year. And if we look at the fourth quarter 2025, all of our four therapeutic areas grew and had a good momentum at the end of the year. In the fourth quarter, we delivered 12% organic growth. If we exclude or normalize for the national sales campaign that we conducted in Q4 2024 and again in Q3 2025. So we see a continued positive momentum in Specialty Pharma, and we see that as a double-digit growth business in terms of what will enable us to continue to deliver on the good growth momentum. We have a two-pronged strategy in terms of organic growth and inorganic growth. From the organic growth perspective, we are focusing, as we discussed before, on cross sales, on innovation and on education, and we see that all those three organic initiatives will drive and contribute to continued good momentum in organic growth in Specialty Pharma.

Arvid Nikator
29:08 - 29:19

But what are they waiting for in terms of the market returning? Is that higher consumer confidence, or what's the inflection point that will drive the market back to normal levels? Just a quick follow-up on that one. How would you characterize the pipeline for 2026 versus 2025, if you would size the growth opportunities?

Unknown 1
29:22 - 29:34

I would. We have a continued good momentum in the business, and we see continued opportunities to expand in existing areas and to find new growth in new areas.

Arvid Nikator
29:38 - 29:39

Okay. Fair enough.

Molly
29:41 - 30:26

And then to your MedTech market question, I think going into 2026, we see the US surgery market condition remaining relatively unchanged. There are signs of stabilization. But I don't think it's a return to healthy growth yet. With that said, we are confident in our strong product portfolio and the brands we offer. And combining that with actions I mentioned we're taking over time, I think we will get back to good growth and also beat the market. But given that we have a new sales team fully in place as of January, we believe that Q1 and spring are still a transition phase. And we see sequential sales improvements quarter by quarter.

Arvid Nikator
30:28 - 30:31

Great. Thanks a lot. Those are all my questions.

Operator
30:35 - 30:39

The next question comes from Adrian Emlin from Nordia. The next question comes from Adrian Emlin from Nordia.

Adrian Emlin
30:42 - 31:14

Hi guys. Pleased to meet you all. And good morning to you as well. I have a few questions, please. So first off, could you provide perhaps some more details here into the field sales organization build out in the MedTech business in the US. And also, we've had a previous question regarding the portfolio streamlining. But could you give some more color on what to expect. This will impact the business over the coming year. Could there be some positive mix effects?

Molly
31:17 - 32:02

I think with the field sales organization in place as of January, we're convinced that that's the right strategy going forward. Being close to our customers and together through our educational platforms and efforts, we do drive growth. Given that it's a new sales team in place and investment we're doing into that, we believe that, as I said before, Q1 and spring will be slightly soft, but over time, with driving sales up on the back of having a strong and present field sales with our customers, that will also drive margin up. With that said, we expect the margin to be fairly flat beginning of the year.

Adrian Emlin
32:05 - 32:15

And there's no specific mix effect with reducing the SKUs there. In terms of gross margins, or EBIT margins.

Molly
32:16 - 32:18

Nothing substantial.

Adrian Emlin
32:19 - 32:29

No. Okay. Another question regarding mixed effects. You had some negative ones in the Pharma business. What should we expect going forward and kind of what were the results there?

Molly
32:32 - 32:52

I think that Specialty Pharma margin, as we guided throughout last year on the back of these investments, has gone down, although there are some mixed effects as well. But we believe the margin will improve throughout the year on the back of these investments, starting to show signs of an effect.

Adrian Emlin
32:54 - 33:11

Right. Okay. And regarding the recruitment of a potential successor for Magnus, what profile are you prioritizing here? And could his departure perhaps prompt any shift in strategy in any way, shape or form?

Molly
33:13 - 33:54

No, I think Magnus has been a very appreciated colleague and has been with Specialty Pharma throughout the last ten years. We believe that, with him departing, we will look for a strong operator, somebody that can help us take the business and continue the successes we've had and take the next step. There are so many more things we believe Specialty Pharma can do and continue to grow. At the same time, the leadership bench within Specialty Pharma and also overall is very strong. So I believe the business is run by our strong operators in the markets. So I'm confident that what we've built up until now will continue to drive similar success in the future.

Adrian Emlin
33:57 - 34:08

Okay. Thanks. Last question here. I don't know if I missed this, but what was the main reason here behind a large change in the operating receivables in the quarter? Is this purely the patent litigation, or did I miss something.

Unknown 1
34:10 - 34:17

To a large extent, this is driven by the patent litigation, as we received €28.7 million in the quarter.

Adrian Emlin
34:21 - 34:22

That was all for me. Thank you very much.

Molly
34:23 - 34:23

What should we expect going forward and what were the results there?

Operator
34:30 - 34:48

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Molly
34:51 - 35:13

No, thank you very much. Thank you for listening in on our Q4 call. As I initially started off with, we are extremely ready for 2026. We delivered a solid finish to 2025, and we look forward to continuing to grow the business together with all the fantastic employees we have within our group. Thank you very much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…